Best AI tools for HEOR and market access teams in 2026

A fluent paragraph is a poor purchasing test. Give each shortlisted tool a question from a live project, such as the comparator landscape for a new indication or the pivotal trials behind a class of therapies, then follow every claim back to its source. A reviewer at a payer or HTA body will do exactly that.

Three checks separate useful tools from risky ones.

• Traceability. Each sentence should point to a record you can open, such as an NCT number or a PMID, and the tool should verify that the identifier exists. General chatbots can invent both, as we explain in why AI invents citations.
• Registry coverage. A relative efficacy argument often starts with trials that are ongoing or completed without a paper. Paper-only search misses them. Check whether the tool reads ClinicalTrials.gov, the EU Clinical Trials Register and WHO ICTRP.
• Shared use. Market access work is done by teams, so ask how seats, limits and exports work. Per-seat credits get awkward when five colleagues touch one dossier.

Be careful with registered endpoints. A registry record shows what investigators planned to measure. Posted results show what was reported, and a publication may use a different population or follow-up. Keep those separate when you move numbers into a model or a slide.

Prices come from vendor pages checked in October 2026 and change often, so confirm before you buy. ClinicalEvidence includes CSV, RIS and BibTeX exports on every plan, with XLSX and DOCX from Research Team.

ClinicalEvidence fits the first phase of HEOR and market access work, when the question is what trials exist for an intervention and its comparators. Run a clinical trial search, read the cited answer, then open the trial table to filter by phase, status, sponsor type and country. Compare two to four interventions side by side to see comparators, endpoints and outcomes across studies.

Alerts on new trials and status changes keep a landscape current between submissions, which matters when a competitor readout can change your comparator set. The export options send the table and references into your reference manager or a working spreadsheet.

It does not replace a formal systematic review or an economic model. Verification shows that a reference exists and supports the sentence, while your team still appraises quality and applicability. Our page for HEOR and regulatory consultants shows how teams use it, and the pricing page lists seat and answer limits.

Elicit belongs on the shortlist when the deliverable begins with a structured evidence table built from papers. Decide which fields your reviewers need, such as population, comparator and endpoint, before you test extraction. Its Clinical Trials feature covers ClinicalTrials.gov only, so European and WHO ICTRP records need another route. Our Elicit alternative page compares the two in detail.

Consensus is quick for a question about published research, and Scite shows whether later papers support or contrast a key finding. Both help when you defend a claim in the literature. Neither is built around trial registries. See the Consensus alternative and Scite alternative pages for the registry-side comparison.

When an HTA body or client expects a documented review with dual screening and an audit trail, buy a platform built for that. DistillerSR, Covidence and Nested Knowledge exist for this work. Use them for the protocol-driven review and use a cited evidence tool upstream for scoping and downstream for refreshing the landscape. If screening is your main need, read our notes on systematic review software.

Start with scoping in ClinicalEvidence to learn which trials, endpoints and comparators exist. Move the relevant set into a review platform if the project needs a formal review. Keep the reference list attached through every step, and let an assistant tidy wording only from sources a person has checked.

When the findings become an internal pricing or access discussion, long payer and HTA agency reports are easier to work through if you can ask questions of the PDF itself and see the page behind each answer. Check those answers against the originals before anything enters the dossier.

What is the best AI tool for HEOR?

There is no single best tool, because HEOR work spans trial evidence, systematic review screening, modelling and dossier writing. For gathering cited trial evidence from registries and PubMed, ClinicalEvidence fits. For screening hundreds of papers in a formal review, use a dedicated review platform. Match each purchase to the deliverable you owe this quarter.

Can AI do a systematic literature review for market access?

AI can speed up search, screening and data extraction, but a payer-grade review still needs a documented protocol and human reviewers. Dedicated systematic review platforms keep the audit trail HTA bodies expect. Use cited evidence tools for scoping and landscape work, then run the formal review in a screening platform.

How is AI used in market access?

Teams use AI mainly for evidence synthesis, such as scoping trial data, extracting study characteristics and drafting referenced summaries. It is used less for economic modelling and submission writing. Every claim still needs a source a reviewer can open, so buy tools that cite records, not tools that only produce fluent text.

Can ChatGPT be used for health economics research?

ChatGPT can help draft and edit text from evidence you have already checked. It can invent NCT numbers and references, so it should not be your source of evidence for a value dossier or model input. Feed it verified material and have a reviewer check every citation.

How much do AI tools for HEOR cost?

ClinicalEvidence Clinician costs 49 USD monthly or 24 USD per month billed yearly (288 USD), and Research Team costs 199 USD monthly or 99 USD per month billed yearly with 3 seats. Elicit Pro costs 49 USD per user per month billed annually. Systematic review platforms and enterprise tools are priced on request.